



Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:

Steel, CM;Walmsley, EA;Anderson, GA;Coles, CA;Ahern, B;White, JD

Title:

Immunohistochemical analysis of laryngeal muscle of horses clinically affected with recurrent laryngeal neuropathy

Date:

2020-10-27

Citation:

Steel, C. M., Walmsley, E. A., Anderson, G. A., Coles, C. A., Ahern, B. & White, J. D. (2020). Immunohistochemical analysis of laryngeal muscle of horses clinically affected with recurrent laryngeal neuropathy. EQUINE VETERINARY JOURNAL, 53 (4), pp.710-717. <https://doi.org/10.1111/evj.13362>.

Persistent Link:

<https://hdl.handle.net/11343/276487>

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30

DR. CATHERINE STEEL (Orcid ID : 0000-0001-7106-7884)

DR. BENJAMIN AHERN (Orcid ID : 0000-0001-5527-8964)

Article type : General Article

Editorial reference code : EVJ-GA-20-105.R1

**Immunohistochemical analysis of laryngeal muscle of horses clinically affected with recurrent laryngeal neuropathy**

C. M. Steel\*<sup>1</sup>, E. A Walmsley<sup>1</sup>, G. A. Anderson<sup>1</sup>, C. A. Coles<sup>2</sup>, B. Ahern<sup>3</sup> and J. D. White<sup>4</sup>

<sup>1</sup>University of Melbourne, School of Veterinary and Agricultural Sciences, Werribee, VIC 3030 Australia;

<sup>2</sup>Murdoch Children’s Research Institute, The Royal Children’s Hospital, Parkville, VIC 3052 Australia;

<sup>3</sup>University of Queensland, School of Veterinary Science, Equine Specialist Hospital, Gatton, QLD 4343 Australia and

<sup>4</sup>Office of the Pro Vice Chancellor Research and Innovation, Charles Sturt University, Wagga Wagga, NSW 2678, Australia.

\*Corresponding author email: [csteel@unimelb.edu.au](mailto:csteel@unimelb.edu.au)

**Keywords:** horse; larynx; muscle fibre types; myosin heavy chain; laryngeal paralysis

**Running title:** Immunohistochemistry of laryngeal muscles of horses with recurrent laryngeal neuropathy

**Abstract**

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as [doi: 10.1111/EVJ.13362](https://doi.org/10.1111/EVJ.13362)

This article is protected by copyright. All rights reserved

31 **Background:** As myosin heavy chain (MyHC) profile of muscle fibres is heavily influenced  
32 by neural input, changes in MyHC expression are expected in horses clinically affected with  
33 recurrent laryngeal neuropathy (RLN) yet this has not been thoroughly investigated.

34 **Objectives:** To describe changes in MyHC and fibre diameter in left cricoarytenoideus  
35 dorsalis muscle (L-CAD) of horses with clinical signs of RLN.

36 **Study design:** Observational cohort study.

37 **Methods:** Immunohistochemistry was used to assess the MyHC-based fibre-type proportion,  
38 size and grouping in the L-CAD of ten Thoroughbred horses, five clinically affected with  
39 RLN and five unaffected controls based on resting endoscopic examination. The Mann-  
40 Whitney U test was used to compare the two groups.

41 **Results:** Compared to controls (of mean age  $3.0 \pm 1.7$  years) which only expressed type I, IIA  
42 and IIX MyHC, the L-CAD of affected horses (of mean age  $2.8 \pm 0.8$  years) had obvious fibre-  
43 type grouping, and despite apparent compensatory hypertrophy of a small number of fibres, a  
44 decrease in overall fibre diameter (median difference  $-35.2 \mu\text{m}$ , 95% CI  $-47.4$  to  $-7.9$ ,  $P$   
45  $=0.02$ ) and diameter of type IIA fibres (median difference  $-46.8 \mu\text{m}$ , 95% CI  $-52.1$  to  $-5.0$ ,  
46  $P=0.03$ ). Anti-fast MyHC (MY32) cross-immunoreacted with embryonic-MyHC. Whereas  
47 MY32-positive fibres were identified as type IIX in controls, in affected horses these fibres  
48 were less than  $50 \mu\text{m}$  diameter with internal nuclei and were MYH3-positive for embryonic  
49 myosin indicating depletion of type IIX fibres yet active regeneration and fibre renewal.

50 **Main limitations:** Small sample size that did not include subclinical cases. Fibre size and  
51 appearance rather than staining colour were relied upon to differentiate embryonic from type  
52 IIX MyHC.

53 **Conclusions:** Horses clinically affected with RLN have overall atrophy of fibres, loss of IIX  
54 fibres and expression of embryonic myosin indicating regenerative capacity. Despite  
55 hypertrophy of some remaining fibres, the overall decline in the bulk of fibres including those  
56 most fatigue resistant may be the critical change that results in failure to maintain arytenoid  
57 abduction during exercise although direct comparison to subclinical cases is needed to  
58 confirm this.

59  
60

## 61 **Introduction**

62 Recurrent laryngeal neuropathy (RLN) is an important performance limiting disease of horses  
63 characterised by progressive loss of large diameter myelinated axons most severe in the distal

64 portions of the left recurrent laryngeal nerve (rLN)[1-3]. Changes in the laryngeal muscles  
65 are characteristic of neurogenic disease that is chronic and repetitive in nature with cyclic  
66 denervation and reinnervation [2; 4]. Although adductor muscles are also affected [5],  
67 dysfunction of the cricoarytenoideus dorsalis muscle (CAD), the only abductor, is clinically  
68 most important. Failure of abduction of the left arytenoid and vocal cord results in respiratory  
69 impairment during inspiration, with resultant decreased athletic performance and abnormal  
70 respiratory noise during exercise.

71

72 With RLN, changes in the laryngeal muscles are evident to varying degrees and include fibre-  
73 type grouping, atrophy of single fibres or groups of muscle fibres, compensatory hypertrophy  
74 of some remaining fibres, and eventual fibrosis and fat replacement [2; 4]. Neuropathologic  
75 changes within the rLN and laryngeal muscle [2; 6] and reduced conduction velocity in the  
76 left rLN [7] also occur in many endoscopically normal horses and these animals are  
77 considered sub-clinically affected.

78

79 The functional demands of muscles are met by a variety of muscle fibre types that have a  
80 range of speed, endurance and power characteristics. Fibre type is determined by expression  
81 of different isoforms of myosin heavy chain (MyHC) [8]. Normal laryngeal muscle of mature  
82 horses is comprised of three fibre types, slow (type I), IIA and IIX [9; 10], expected to  
83 provide motor units of this muscle with a tenfold range of speeds [11]. Embryonic-MyHC is  
84 not normally present in adult muscle yet is transiently re-expressed during muscle  
85 regeneration following injury or disease and can be used to identify regenerating muscle  
86 fibres [12-14]. As altered neural input occurs with RLN and MyHC profile is heavily  
87 influenced by neural input [15], changes in MyHC profile occur in this disease [9].

88 Knowledge of fibre type distribution is essential for our understanding of laryngeal function,  
89 RLN and adaptive mechanisms that enable subclinical horses to remain asymptomatic. In the  
90 left CAD muscle (L-CAD) of horses considered sub-clinically affected with RLN there was  
91 virtual elimination of type IIX fibres, a lower proportion of slow fibres, greater abundance of  
92 IIA fibres, and hypertrophy of many remaining slow and IIA fibres [9; 10]. Loss of type IIX,  
93 the fastest fibres present in equine laryngeal muscle, is expected to be associated with a  
94 reduction of the speed range of laryngeal muscles from 10-fold to only 4-fold [11] and may  
95 explain some of the alterations in movement of the left arytenoid cartilage observed in horses  
96 with partial paralysis. Yet as these horses can maintain laryngeal abduction during exercise,  
97 loss of IIX fibres appears tolerated and we assume hypertrophy of remaining fatigue resistant

98 fibres allows horses to remain subclinical. Whilst this suggests that nerve fibres innervating  
99 IIX muscle fibres are more susceptible to damage incurred by RLN, the sub-clinically  
100 affected horses reported by Rhee and others [9] were at least 10 years of age and horses  
101 clinically affected with RLN were not included.

102  
103 We aimed to identify changes in MyHC expression and fibre diameter in the L-CAD muscle  
104 of horses with clinical signs of RLN and hypothesised that these horses would have loss of  
105 IIX fibres, a reduction in the bulk of slow (type I) fibres and expression of embryonic-MyHC.

106

## 107 **Materials and Methods**

108 A section of muscle, 5-10 mm in diameter and approximately 10 mm in length, was dissected  
109 from the mid-belly of the lateral compartment of the L-CAD from a convenience sample of  
110 five clinically affected (RLN group) and five endoscopically normal Thoroughbred horses  
111 (controls) in race training. Samples from the RLN group were collected during prosthetic  
112 laryngoplasty surgery from horses with Havemeyer grade III.2 or greater [16] on resting  
113 laryngoscopic examination and a history of exercise intolerance. Control samples were  
114 collected from horses with normal laryngeal function (Havemeyer grade I) on resting  
115 endoscopic examination immediately after euthanasia for unrelated reasons. Endoscopic  
116 examination was performed within 24 hours of sample collection in all horses and laryngeal  
117 function was graded by the same observer. Samples were identified by number only to ensure  
118 blinding when obtaining the measurements.

119

120 Immediately following collection, muscle samples were coated with OCT compound, snap  
121 frozen in isopentane quenched liquid nitrogen and stored at -80°C until immunofluorescent  
122 staining. Frozen muscle samples were mounted using OCT compound to allow cutting of  
123 10µm transverse sections in a cryostat at -20°C. Staining was performed immediately  
124 following sectioning using a methodology based on that reported by Tulloch *et al.* [17]. All  
125 antibodies were directly conjugated to ALEXA dyes using the Zenon labelling technology.  
126 Type I fibres (slow) were sequentially labelled with NOQ7.5.4D (ALEXA350) and type IIA  
127 (fast) with N2.261 (ALEXA488). MY32 antibody was used (which identifies all type 2  
128 fibres) labelled with ALEXA594. With this staining regime under fluorescence type I fibres  
129 will appear green, type IIA fibres yellow/orange and remaining fast fibres (type IIX) appear  
130 red. Separate transverse muscle cryosections (10µm) were stained for embryonic myosin  
131 using a mouse anti-MYH3 antibody (clone F1.652) in combination with ALEXA594 labelled

132 MY32 as described above to confirm cross reactivity of the two antibodies. These sections  
133 were blocked in 10% (v/v) donkey serum (Millipore, Billerica, Massachusetts, USA) in wash  
134 buffer (0.1% Tween, 0.5% BSA in 1xPBS) for one hour, and then incubated with the primary  
135 antibody anti-MYH3 (Santa Cruz Biotechnology, 1:200), for 60 minutes at room temperature.  
136 The sections were washed in PBS and then incubated with the fluorescent secondary  
137 antibody, donkey anti-rat IgG Alexa Fluor 488 (Life Technologies, 1:250) in the dark for 90  
138 minutes. Nuclei were stained in all sections with 1 µg/µl Hoechst (Life Technologies) in PBS  
139 for one minute before mounting with polyvinyl alcohol with glass coverslips.

140

141 Digital images were captured on a Zeiss Axio Imager M1 upright fluorescent microscope  
142 with an AxioCam MRm camera running AxioVision software V4.8.2.0 (Carl Zeiss,  
143 Oberkochen, Germany). A minimum of five images were collected per section at 100x  
144 magnification to allow the analysis of a minimum of 250 fibres. Analysis of images was  
145 performed by the same observer using Image J (National Institute of Health, version  
146 1.8.0\_1121) with each individual fibre being traced, categorised based on myosin staining  
147 pattern and the minimum Feret's diameter (defined as the closest possible distance between  
148 two parallel tangents of the muscle fibre) automatically calculated by the software.

149

150 Prism 8.3.1 (Graphpad Software, San Diego, CA) was used for statistical analysis. The  
151 coefficient of variation (CV%) for each horse and fibre type was defined as (standard  
152 deviation of fibre diameters/mean of fibre diameters) x 100. The Shapiro-Wilk test was used  
153 to test for normality of values for each group of five control horses and each group of five  
154 affected horses. Three of these 22 groups were not normally distributed and each of these  
155 three groups had a statistical outlier. These groups were proportion of type IIX/embryonic  
156 fibres in the control group, fibre diameter of type IIA fibres in the affected group and CV% of  
157 type IIX/embryonic fibres in the affected group. The distributions of the affected and control  
158 groups were compared using the Mann-Whitney U test. The Hodges-Lehmann (H-L) estimate  
159 of the difference between two population medians was estimated as the median of the set of  
160 25 (5 by 5) differences between each value in the affected group and each value in the control  
161 group. A p-value <0.05 was considered significant.

162

## 163 **Results**

164 Ten Thoroughbred horses including five clinically affected with RLN mean age 2.8 [SD 0.8]  
165 years and with resting endoscopic grade [16] of III.2 (2 horses) or III.3 (3 horses) and five

166 endoscopically normal (grade I) mean age 3.0 [SD 1.7] years were used (Table 1). The L-  
167 CAD muscle of affected horses (RLN group) had obvious fibre-type grouping with groups of  
168 small diameter fibres of the same type and hypertrophy of some remaining fibres (Figure 1A)  
169 while control horses had a normal mosaic fibre pattern (Figure 1B). Although the proportion  
170 of each fibre type did not appear to differ in the L-CAD muscle of clinically affected horses  
171 compared to controls (Table 2), anti-fast MyHC antibody cross-reacts with developmental  
172 MyHC forms [18] and so the double staining technique used did not differentiate embryonic  
173 from IIX fibres. There was a significant decrease in overall fibre diameter in affected horses  
174 ( $p=0.02$ ); Table 3). This included a significant decrease in median fibre diameter of type IIA  
175 ( $p=0.03$ ) and embryonic/IIX ( $p=0.008$ ) fibres in clinically affected horses, although the  
176 distribution in fibre sizes did indicate the presence of a small number of larger fibres  
177 suggesting some potential hypertrophic compensation (Figure 2). The smaller diameter (less  
178 than 50  $\mu\text{m}$ ) of most of the fibres stained positive for type IIX/embryonic and internally  
179 placed nuclei indicated active regeneration and fibre renewal consistent with embryonic  
180 myosin and depletion of IIX fibres. Importantly, in the additional sections stained using anti-  
181 MYH3 (anti-embryonic), embryonic-MyHC was only observed in the affected animals with a  
182 total absence in controls (Figure 3).

183  
184 In control samples considered to be normal the extent of variation in myofibre diameter  
185 through calculating a coefficient of variation or CV% (Table S1) was consistent across all  
186 fibre types and when all fibre diameters were considered as a group. In comparison, the  
187 extent of variation in clinically affected samples was consistently higher indicating changes  
188 most likely related to processes such as denervation, compensatory hypertrophy and  
189 regenerative myogenesis. However, in samples from clinically affected horses, the  
190 distribution of embryonic/IIX fibre sizes showed a distinct pattern. This was attributed to  
191 regenerative myogenesis (embryonic MyHC positive) with a tight peak (with little variation)  
192 of fibre diameters less than 50 $\mu\text{m}$  and less than the smallest type IIX fibres in controls.

193

## 194 **Discussion**

195 Despite compensatory hypertrophy of some remaining fibres, we identified an overall  
196 decrease in muscle fibre diameter, loss of IIX fibres and presence of embryonic fibres in  
197 Thoroughbred racehorses clinically affected with RLN. There was a shift to smaller diameter  
198 type IIA fibres with disease yet for type I fibres the reduction in median diameter was not  
199 significant. We previously reported loss of type IIX fibres, no change in the proportion yet

200 significantly fewer type I and IIA fibres per microscopic field in the L-CAD of four horses  
201 with advanced RLN [10]. Indeed, gross atrophy of the L-CAD muscle is usual in clinically  
202 affected animals. A left to right ratio  $<0.8$  of CAD muscle thickness measured using  
203 transoesophageal ultrasound correlated with muscle volume and predicted dynamic collapse  
204 (exercising grade C)[19]. Furthermore, an increase in type I fibres was observed in laryngeal  
205 muscle of Thoroughbred racehorses in training (E. Walmsley, personal communication). On  
206 these bases we theorised that clinically affected horses might have lost a critical volume of  
207 the most fatigue-resistant slow (type I) fibres in addition to faster type IIA and fastest type  
208 IIX fibres. Although loss of the aforementioned fibre-types might be the critical factor in  
209 determining whether horses are clinically affected with RLN with failure to maintain  
210 arytenoid abduction during exercise we were unable to confirm this when comparing this  
211 small sample size of horses. Even minor loss of slow fibres would drastically reduce dynamic  
212 range of contraction speeds and reduce the capacity of the L-CAD muscle to endure sustained  
213 periods of abduction. Such functional loss is sometimes detected on endoscopic examination  
214 during high speed exercise in horses with partial laryngeal paralysis. Further evaluation of the  
215 impact of RLN on the bulk of type I fibres with advancing disease required.

216

217 Embryonic myosin was only identified in clinically affected horses, all with obvious or  
218 marked abductor deficit and failure to achieve and maintain abduction yet not complete  
219 immobilisation of the arytenoid cartilage and vocal fold (i.e. Havemeyer grade III.2 and III.3)  
220 [16]. This indicates that affected horses maintain regenerative capacity, an important finding  
221 as it suggests that surgical reinnervation likely remains possible unless extensive muscle  
222 fibrosis occurs. This regenerative capacity may also preserve some muscle function for a  
223 period of time following onset of disease. We had predicted that with advanced denervation  
224 in clinically affected horses muscle fibre regeneration would be stimulated [20], that  
225 denervated fibres would express embryonic-MyHC isoforms [20-22] and as surviving nerve  
226 fibres would no longer be able to maintain a functionally sufficient population of remaining  
227 muscle fibres that marked atrophy would occur. Indeed, this was observed in clinically  
228 affected horses in the current study. In earlier work by the first author and others, a  
229 significant increase in the number of myonuclei per muscle fibre, central nuclei, and  
230 activation of muscle satellite cells was observed in the L-CAD muscle from clinically  
231 affected horses regardless of age, degree of atrophy or duration of disease. The latter finding  
232 suggests that the muscle is attempting to regenerate by intrinsic muscle satellite cell  
233 activity[10].

234

235 As discussed earlier some horses with normal laryngeal function have subclinical disease.  
236 Rhee *et al.* described loss of the fastest (type IIX) fibres in laryngoscopically normal horses  
237 (all >10 years of age) with no history of exercise intolerance and considered sub-clinically  
238 affected based on fibre-type grouping [9]. Based on these findings it appears that loss of IIX  
239 fibres may be well tolerated. This earlier study also provided insight into adaptive  
240 mechanisms that enable subclinical horses to remain clinically unaffected as these horses also  
241 demonstrated a decrease in the proportion of slow fibres suggesting some loss of slow fibres  
242 follows the loss of type IIX fibres, yet an increase in the proportion of type IIA fibres and  
243 hypertrophy of remaining slow and type IIA fibres [9]. The present study considered  
244 clinically normal horses compared to those with diagnosed clinical disease. In unaffected  
245 horses in both studies type IIA fibres predominated in the L-CAD followed by slow (type I)  
246 fibres and relatively few type IIX. The virtual absence of type IIX fibres in the LCAD of sub-  
247 clinical horses [9] is consistent with our results in clinically affected samples in that the  
248 central position of the nucleus, the small diameters (vast majority were smaller than the  
249 smallest fibres in the control samples) and the cross reactivity with embryonic MyHC  
250 indicate an absence of IIX fibres. While sub-clinical samples show overall hypertrophy of  
251 remaining type IIA and slow (type I) fibres [9] our data shows a shift to smaller fibres. This is  
252 probably related to severity of disease and the chronic nature of the denervation.

253

254 While the exact prevalence of subclinical disease is unknown, pathologic changes in the rLN  
255 and laryngeal muscles are present in 30% or more of horses [1; 5; 7; 23-25]. As a result, we  
256 expected to encounter subclinical disease in some of the control horses in the current study,  
257 yet fibre-type grouping was not observed in this group. We propose that this may have been  
258 due to the age of horses (6 years or less) and the small sample size. Similarly, muscles  
259 without fibre-type grouping reported by Rhee *et al.* were from horses aged 2 and 6 years (and  
260 from a third horse of unknown age) [9]. Study of a larger number of horses would be  
261 necessary to identify fibre-type grouping in young horses without clinical signs of RLN.  
262 Then, the direct comparison of L-CAD muscle samples from subclinical and clinically  
263 affected, age and training status matched, young horses stained using the same method may  
264 be undertaken to improve our understanding of the critical point at which subclinical disease  
265 becomes clinical.

266

267 As expected based on findings in horses with subclinical disease [9], the loss of type IIX  
268 fibres identified in clinically affected horses in the current study was also predicted. Loss of  
269 the largest myelinated axons occurs in RLN with loss of the fastest conduction velocity nerve  
270 impulses expected. As these nerve fibres innervate type IIX muscle fibres (the fastest fibres  
271 present in the equine CAD muscle[9]), it follows that type IIX fibres are more susceptible to  
272 damage incurred by equine RLN, or their signals more easily corrupted than those  
273 innervating type IIA or type I (slow) fibres. It should be noted, however, that an antibody that  
274 specifically reacts with MyHC-IIX was not used to identify type IIX fibres in the current  
275 study. Attempts in our laboratory to use a specific MyHC-IIX monoclonal antibody have  
276 been unsuccessful. With the double staining method used, both type IIX and embryonic fibres  
277 stain red, yet the smaller diameter (less than 50  $\mu\text{m}$ ) of the majority of fibres and internally  
278 placed nuclei indicating active regeneration and fibre renewal identified positive stained  
279 fibres as expressing embryonic myosin in affected horses. This was supported by positive  
280 staining for embryonic fibres using anti-MyH3 (anti-embryonic) on additional sections.

281

282 As expected there was obvious fibre-type grouping in clinically affected horses in addition to  
283 scattered angular fibres, groups of atrophied fibres and some remaining hypertrophied fibres  
284 with central nuclei [26]. Fibre-type grouping is a diagnostic sign of early neuropathy and an  
285 indicator of partial denervation followed by reinnervation of muscle fibres by intact nerve  
286 terminals of neighbouring fibres [27]. Clusters of muscle fibres acquire the same  
287 histochemical properties since neural influence determines fibre-type and changes represent  
288 ongoing, continual or intermittent nerve injury with repeated attempts at reinnervation. In  
289 comparison, although surgical transection of the rLN results in immediate laryngeal paralysis,  
290 it does not result in fibre-type grouping and changes in MyHC profile differ from those seen  
291 with naturally occurring disease [10; 28].

292

293 We only included Thoroughbred horses of racing age. This is likely important as ageing-  
294 related changes in the expression of MyHC fibres have been observed in aged horses [29-32].  
295 Furthermore, we only included horses in race training as the intensity and duration of training  
296 may influence MyHC fibre type not only in equine locomotor muscles [29; 33] but also in  
297 laryngeal muscle. On this basis, as mentioned earlier, our preliminary investigations of gene  
298 expression for MyHC fibre type in laryngeal muscle of trained compared to untrained  
299 Thoroughbreds suggests that there is upregulation of slow MyHC with training (i.e. a shift

300 towards a slower fibre type occurs as a training adaptation in laryngeal muscle as it does in  
301 gluteal muscle) (E. Walmsley *et al.*, personal communication).

302

303 A limitation of the current study is that the sample size might not have been large enough to  
304 detect any decrease in the proportion and mean diameter of type I fibres in affected horses  
305 compared to controls. In addition, none of the affected horses had complete immobility of the  
306 left arytenoid and vocal cord on resting endoscopy. The total bulk of type I fibres may be  
307 critical in maintaining abduction during exercise and this might not be reflected by  
308 considering the proportion of type I fibres or their mean diameter in isolation. A further  
309 limitation of the current study is that laryngeal function was assessed at rest but not by  
310 dynamic endoscopy during exercise and although resting laryngeal function is reasonably  
311 sensitive and highly specific for predicting laryngeal function at exercise [34] we cannot be  
312 entirely sure that all control horses had normal laryngeal function during exercise. However,  
313 we only included horses with a known history of normal exercise tolerance in the control  
314 group and with exercise intolerance in the affected group.

315

316 In conclusion, horses clinically affected with RLN have an overall decrease in muscle fibre  
317 diameter attributed to a reduction in size of IIA fibres, depletion of IIX fibres and expression  
318 of embryonic myosin indicating remaining potential for regeneration. Although there is  
319 hypertrophy of some remaining fibres, we propose that the overall loss of bulk of more  
320 fatigue resistant muscle fibres and not simply loss of IIX fibres, which appears tolerated as it  
321 occurs in subclinical horses[9], results in the failure to maintain arytenoid abduction during  
322 exercise. Longitudinal studies are required to identify changes over time and to identify cut-  
323 off points for L-CAD muscle volume and more specifically for type I fibre bulk that  
324 differentiate dynamic collapse from horses able to maintain adequate abduction during  
325 exercise.

326

#### 327 Authors' declaration of interests

328 No competing interests have been declared.

329

#### 330 Ethical animal research

331 This study was approved by the University of Melbourne Animal Ethics Committee.

332

333 **Owner informed consent**

334 Client consent was obtained for inclusion in the study.

335

336 **Data accessibility statement**

337 The data that support the findings of this study are available from the corresponding author  
338 upon reasonable request.

339

340 **Source of funding**

341 None.

342

343 **Authorship**

344 C. Steel, E. Walmsley, B. Ahern and J. White contributed to study design. C. Steel, E. Walmsley,  
345 C. Coles and J. White contributed to study execution. C. Steel, G. Anderson and J. White  
346 contributed to data analysis and interpretation. C. Steel, E. Walmsley, J. White and G. Anderson  
347 contributed to preparation of the manuscript. All authors gave their final approval of the  
348 manuscript. G. Anderson and J. White had access to all the data in the study and take  
349 responsibility for the integrity of the data and the accuracy of the data analysis.

350

351

352 **Figure legends**

353 **Figure 1A:** Transverse sections of the left cricoarytenoideus dorsalis muscle of a 3-year-old  
354 Thoroughbred entire male with recurrent laryngeal neuropathy (grade III.2). A sequential  
355 double-staining immunofluorescent technique was used (type I fibres are labelled with  
356 NOQ7.5.4D [ALEXA350], type IIA with N2.261 [ALEXA488] and all remaining type II fibres  
357 and embryonic with MY32 antibody [ALEXA594]). Type I fibres are stained green, type IIA  
358 yellow-orange and small red staining fibres are considered embryonic fibres due to their small  
359 size and internal nuclei. Additional immunolabelling with 1µg/µl Hoechst identifies all nuclei  
360 (blue staining). Fibre-type grouping and marked reduction in the diameter of type IIA and some  
361 type I fibres is evident.

362

363 **Figure 1B:** Transverse cryostat section of the left cricoarytenoideus dorsalis muscle of a 3-  
364 year-old Thoroughbred gelding with normal (grade I) laryngeal function on endoscopic

365 examination at rest. The staining protocol used was the same as for figure 1A. There is a  
366 normal mosaic pattern with a predominance of type IIA fibres (yellow orange), fewer type I  
367 (green), and a small number of type IIX (red) staining fibres. Nuclei are stained blue. Scale  
368 bar = 100  $\mu$ m.

369

370 **Figure 2:** Distribution of muscle fibres by diameter for type I (a), type IIA (b) and type IIX  
371 or embryonic-MyHC in the left cricoarytenoideus dorsalis muscle of horses clinically  
372 affected with recurrent laryngeal neuropathy (affected) compared to endoscopically normal  
373 horses (controls). Note that although the double staining technique used could not  
374 differentiate embryonic from IIX fibres, the smaller diameter (<50  $\mu$ m) of most red-staining  
375 fibres together with internally placed nuclei evident on stained sections (not shown) indicated  
376 active regeneration and fibre renewal consistent with embryonic myosin in affected but not  
377 control horses.

378

379 **Figure 3:** Transverse sections of biopsy samples of left cricoarytenoideus dorsalis muscle  
380 from an unaffected (control) horse (A and C) and a horse clinically affected with recurrent  
381 laryngeal neuropathy (B and D). There is a lack of positively stained fibres in the negative  
382 control samples (IgG only) from the unaffected (A) and affected (B) horse. Lack of staining  
383 is also evident with embryonic MyHC staining of a sample from an unaffected horse (C) but  
384 in the affected horse (D) many regenerating fibres reactive for embryonic myosin (green  
385 staining) and demonstrating internal nuclei are evident. Sections are stained using anti-  
386 MYH3 as the primary antibody and a secondary fluorescent (green) antibody. Additional  
387 labelling identifies nuclei (blue staining). Scale bar = 100  $\mu$ m.

388

389

390 **Table 1:** Age, sex and resting grade of laryngeal function of Thoroughbred racehorses

Group	Age (years)	Sex	Havemeyer grade* of resting laryngeal function
Control	2.0	Male entire	1
	2.0	Male castrate	1
	2.0	Male castrate	1
	3.0	Male castrate	1
	6.0	Female	1
RLN Group	2.0	Male castrate	3.2

2.5	Male castrate	3.2
2.5	Male entire	3.3
3.0	Male entire	3.3
4.0	Male castrate	3.3

391

392 RLN = Recurrent Laryngeal Neuropathy. \*From Robinson (2004) Havemeyer grade 1: All arytenoid  
 393 cartilage movements are synchronous and symmetrical and full arytenoid cartilage abduction can be  
 394 achieved and maintained; grade 3.2: Obvious arytenoid abductor deficit and arytenoid asymmetry and  
 395 full abduction is never achieved; grade 3.3 Marked but not total arytenoid abductor deficit and  
 396 asymmetry with little arytenoid movement. Full abduction is never achieved.

397

398

399 **Table 2:** Percentage of each muscle fibre type in the left cricoarytenoideus dorsalis muscle  
 400 based on double-staining immunofluorescent technique (type I fibres are labelled with  
 401 NOQ7.5.4D [ALEXA350], type IIA with N2.261 [ALEXA488] and all remaining type II and  
 402 embryonic fibres with anti-MY32 [ALEXA594]).

Fibre	Group	N	Median	Min	Max	H-L Diff	95% CI	p-value
Type I	Control	5	26.18	11.36	35.25	-0.02	-19.44 to 32.78	>0.9
	Affected	5	15.91	12.04	58.96			
Type IIA	Control	5	64.51	56.91	87.88	-8.61	-37.02 to 21.60	0.5
	Affected	5	61.93	33.96	86.11			
Type IIX/embryonic	Control	5	2.84	0.38	22.65	6.71	-9.58 to 21.01	0.2
	Affected	5	13.07	1.85	23.85			

403

404 H-L Diff: Hodges-Lehmann estimate of the difference between two population medians. CI: Confidence interval

405

406

407 **Table 3:** Muscle fibre size (Feret's minimum diameter,  $\mu\text{m}$ ) in the left cricoarytenoideus  
 408 dorsalis muscle of horses clinically affected with recurrent laryngeal neuropathy compared to  
 409 unaffected control horses

Fibre	Group	n	Median	Min	Max	H-L	95% CI	p-value
						Diff		
Type I	Control	5	78.03	68.97	94.80			
	Affected	5	69.47	50.67	94.79	-11.10	-31.84 to 16.76	0.2
Type IIA	Control	5	83.48	74.76	86.36			
	Affected	5	36.64	33.08	78.50	-46.84	-52.12 to -4.98	0.03
Type								
IIX/embryonic	Control	5	64.86	34.73	89.99			
	Affected	5	20.99	20.46	30.26	-43.44	-69.00 to -13.74	0.008
All Fibres	Control	5	82.70	73.80	88.25			
	Affected	5	45.42	35.42	74.80	-35.22	-47.44 to -7.90	0.02

410

411 H-L Diff: Hodges-Lehmann estimate of the difference between two population medians. CI: Confidence interval

412

413

#### 414 Supporting Information

415 **Table S1:** Coefficient of variation (CV%) of fibre diameter in the left cricoarytenoideus  
 416 dorsalis muscle of horses clinically affected with recurrent laryngeal neuropathy compared to  
 417 unaffected control horses.

418

#### 419 References

420 [1] Cahill, J.I. and Goulden, B.E. (1986) Equine laryngeal hemiplegia. Part I. A  
 421 light microscopic study of peripheral nerves. *N Z Vet J* **34**, 161-169.

422

423 [2] Duncan, I.D., Griffiths, I.R., McQueen, A. and Baker, G.O. (1974) The  
 424 pathology of equine laryngeal hemiplegia. *Acta Neuropathol* **27**, 337-348.

425

426 [3] Hahn, C., Matiasek, K., Dixon, P., Molony, V., Rodenacker, K. and Mayhew, I.  
 427 (2008) Histological and ultrastructural evidence that recurrent laryngeal  
 428 neuropathy is a bilateral mononeuropathy limited to recurrent laryngeal  
 429 nerves. *Equine Vet J* **40**, 666-672.

430

431 [4] Duncan, I.D., Reifenrath, P., Jackson, K.F. and Clayton, M. (1991)  
 432 Preferential denervation of the adductor muscles of the equine larynx. II:  
 433 Nerve pathology. *Equine Vet J* **23**, 99-103.


434

- 435 [5] Lopez-Plana, C., Sautet, J.Y. and Ruberte, J. (1993) Muscular pathology in  
436 equine laryngeal neuropathy. *Equine Vet J* **25**, 510-513.  
437
- 438 [6] Duncan, I.D., Baker, G.J., Heffron, C.J. and Griffiths, I.R. (1977) A correlation  
439 of the endoscopic and pathological changes in subclinical pathology of the  
440 horse's larynx. *Equine Vet J* **9**, 220-225.  
441
- 442 [7] Cercone, M., Hokanson, C.M., Olsen, E., Ducharme, N.G., Mitchell, L.M.,  
443 Piercy, R.J. and Cheetham, J. (2019) Asymmetric recurrent laryngeal nerve  
444 conduction velocities and dorsal cricoarytenoid muscle electromyographic  
445 characteristics in clinically normal horses. *Sci Rep* **9**, 2713.  
446
- 447 [8] Bottinelli, R., Schiaffino, S. and Reggiani, C. (1991) Force-velocity relations  
448 and myosin heavy chain isoform compositions of skinned fibres from rat  
449 skeletal muscle. *J Physiol* **437**, 655-672.  
450
- 451 [9] Rhee, H.S., Steel, C.M., Derksen, F.J., Robinson, N.E. and Hoh, J.F. (2009)  
452 Immunohistochemical analysis of laryngeal muscles in normal horses and  
453 horses with subclinical recurrent laryngeal neuropathy. *J Histochem*  
454 *Cytochem* **57**, 787-800.  
455
- 456 [10] Steel, C., Walmsley, E., Fulton, I., Kingham, P., Hoh, J, Rhee, H. (2010)  
457 Roarers- Recurrent Laryngeal Neuropathy in Horses *Rural Industries*  
458 *Research and Development Corporation Pub No. 10/163*.  
459
- 460 [11] Rome, L.C., Sosnicki, A.A. and Goble, D.O. (1990) Maximum velocity of  
461 shortening of three fibre types from horse soleus muscle: implications for  
462 scaling with body size. *J Physiol* **431**, 173-185.  
463
- 464 [12] d'Albis, A., Couteaux, R., Janmot, C., Roulet, A. and Mira, J.C. (1988)  
465 Regeneration after cardiotoxin injury of innervated and denervated slow and  
466 fast muscles of mammals. Myosin isoform analysis. *Eur J Biochem* **174**, 103-  
467 110.  
468

- 469 [13] Schiaffino, S., Gorza, L., Dones, I., Cornelio, F. and Sartore, S. (1986) Fetal  
470 myosin immunoreactivity in human dystrophic muscle. *Muscle Nerve* **9**, 51-58.  
471
- 472 [14] Sartore, S., Gorza, L. and Schiaffino, S. (1982) Fetal myosin heavy chains in  
473 regenerating muscle. *Nature* **298**, 294-296.  
474
- 475 [15] Rhee, H.S., Lucas, C.A. and Hoh, J.F. (2004) Fiber types in rat laryngeal  
476 muscles and their transformations after denervation and reinnervation. *J*  
477 *Histochem Cytochem* **52**, 581-590.  
478
- 479 [16] Robinson, N. (2004) Consensus statements on equine recurrent laryngeal  
480 neuropathy: conclusions of the Havemeyer Workshop: September 2003,  
481 Stratford-Upon-Avon, Warwickshire, UK. *Equine Vet Educ* **16**, 333-336.  
482
- 483 [17] Tulloch, L., Perkins, J. and Piercy, R. (2011) Multiple immunofluorescence  
484 labelling enables simultaneous identification of all mature fibre types in a  
485 single equine skeletal muscle cryosection. *Equine Vet J* **43**, 500-503.  
486
- 487 [18] Harris, A.J., Fitzsimons, R.B. and McEwan, J.C. (1989) Neural control of the  
488 sequence of expression of myosin heavy chain isoforms in foetal mammalian  
489 muscles. *Development* **107**, 751-769.  
490
- 491 [19] Kenny, M., Cercone, M., Rawlinson, J., Ducharme, N., Bookbinder, L.,  
492 Thompson, M. and Cheetham, J. (2017) Transoesophageal ultrasound and  
493 computer tomographic assessment of the equine cricoarytenoid dorsalis  
494 muscle: Relationship between muscle geometry and exercising laryngeal  
495 function. *Equine Vet J* **49**, 395-400.  
496
- 497 [20] Shinnars, M.J., Goding, G.S. and McLoon, L.K. (2006) Effect of recurrent  
498 laryngeal nerve section on the laryngeal muscles of adult rabbits. *Otolaryngol*  
499 *Head Neck Surg* **134**, 413-418.  
500


- 501 [21] Janmot, C. and d'Albis, A. (1994) Electrophoretic separation of  
502 developmental and adult rabbit skeletal muscle myosin heavy chain isoforms:  
503 example of application to muscle denervation study. *FEBS Lett* **353**, 13-15.  
504
- 505 [22] Jakubiec-Puka, A., Kordowska, J., Catani, C. and Carraro, U. (1990) Myosin  
506 heavy chain isoform composition in striated muscle after denervation and self-  
507 reinnervation. *Eur J Biochem* **193**, 623-628.  
508
- 509 [23] Gunn, H. (1972) Histochemical observations on laryngeal skeletal muscle  
510 fibres in 'normal' horses. *Equine Vet J* **4**, 144-148.  
511
- 512 [24] Cahill, J.I. and Goulden, B.E. (1986) Equine laryngeal hemiplegia. Part IV.  
513 Muscle pathology. *N Z Vet J* **34**, 186-190.  
514
- 515 [25] Duncan, I., Griffiths, I. and Madrid, R. (1978) A light and electron microscopic  
516 study of the neuropathy of equine idiopathic laryngeal hemiplegia. *Neuropath  
517 Appl Neuro* **4**, 483-501.  
518
- 519 [26] Duncan, I.D., Amundson, J., Cuddon, P.A., Sufit, R., Jackson, K.F. and  
520 Lindsay, W.A. (1991) Preferential denervation of the adductor muscles of the  
521 equine larynx. I: Muscle pathology. *Equine Vet J* **23**, 94-98.  
522
- 523 [27] Karpati, C. and Engel, W. (1968) "Type grouping" in skeletal muscles after  
524 experimental reinnervation. *Neurology* **18**, 447-447.  
525
- 526 [28] Chalmers, H.J., Caswell, J., Perkins, J., Goodwin, D., Viel, L., Ducharme,  
527 N.G. and Piercy, R.J. (2016) Ultrasonography detects early laryngeal muscle  
528 atrophy in an equine neurectomy model. *Muscle Nerve* **53**, 583-592.  
529
- 530 [29] Kawai, M., Minami, Y., Sayama, Y., Kuwano, A., Hiraga, A. and Miyata, H.  
531 (2009) Muscle fiber population and biochemical properties of whole body  
532 muscles in Thoroughbred horses. *Anat Rec (Hoboken)* **292**, 1663-1669.  
533

- 534 [30] Rivero, J.L., Galisteo, A.M., Aguera, E. and Miro, F. (1993) Skeletal muscle  
535 histochemistry in male and female Andalusian and Arabian horses of different  
536 ages. *Res Vet Sci* **54**, 160-169.  
537
- 538 [31] Alev, K., Leisson, K., Kaasik, P., Jaakma, Ü. and Seene, T. (2011) Age-  
539 related changes in myosin light and heavy chain isoforms' composition in  
540 gluteus medius muscle of sedentary Akhal-Teke horses. *J Equine Vet Sci* **31**,  
541 650-654.  
542
- 543 [32] Ronéus, M. (1993) Muscle characteristics in Standardbreds of different ages  
544 and sexes. *Equine Vet J* **25**, 143-146.  
545
- 546 [33] Leisson, K., Jaakma, Ü. and Seene, T. (2008) Adaptation of equine locomotor  
547 muscle fiber types to endurance and intensive high speed training. *J Equine*  
548 *Vet Sci* **28**, 395-401.  
549
- 550 [34] Elliott, S. and Cheetham, J. (2019) Meta - analysis evaluating resting  
551 laryngeal endoscopy as a diagnostic tool for recurrent laryngeal neuropathy in  
552 the equine athlete. *Equine Vet J* **51**, 167-172.  
553  
554



evj\_13362\_f1a.jpg


Author Mail



evj\_13362\_f1b.jpg


Author Mail

# Type I




evj\_13362\_f2a.jpg

## Type IIA




evj\_13362\_f2b.jpg

## Type IIX (embryonic)



evj\_13362\_f2c.jpg



evj\_13362\_f3.jpg

Author N